Celebrating 20 years of innovation - Discover how we've been a catalyst for regional growth and UK innovation for over two decades in CPI's Annual Review 2023-2024.
High Value Manufacturing Catapult signs MoU with Greater Manchester to provide £1.7 billion manufacturing boost
The HVM Catapult joins forces with Innovation Greater Manchester and Greater Manchester Combined Authority to drive industrial transformation.
Nov 16 2022
Supporting innovation and growth through the UK Community Renewal Fund
With funding from the UK Community Renewal Fund via the Northeast LEP, we’ve enabled two battery businesses to move to the region, with one investing £3m.
Oct 31 2022
Founder of Investing Women Angels and AccelerateHER joins CPI Board
Jackie Waring joins our Board as Non-Executive Director, making her the fifth new Board member in 2022.
Oct 11 2022
Our new RNA Centre of Excellence and RNA Training Academy are set to open
Funded by £10.65 million from the UK Government’s Vaccine Taskforce to support the development, scale-up, and manufacture of RNA vaccines and therapies.
Oct 07 2022
New Manchester-based partnership set to catalyse innovation and regional growth
We’ve signed a Memorandum of Understanding with The University of Manchester in a bid to boost economic growth and deliver impact.
Oct 04 2022
Cellnex UK partners with CPI to accelerate HealthTech innovation with new 5G testbed
We’ve partnered with Cellnex UK to launch a new private 5G testbed for demonstrating and commercialising HealthTech innovations.
Sept 21 2022
CPI joins the Sustainable Medicines Partnership
We’ve joined the YewMaker-led Sustainable Medicines Partnership (SMP) to improve the sustainability of medicines, their manufacturing and supply chains.
Aug 24 2022
Mayor hails “fantastic” arrival of the High Value Manufacturing Catapult and CPI in Manchester
We’ve taken up a new office at Bruntwood SciTech’s Circle Square in Manchester.
Aug 23 2022
CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine
$30m funding will be provided to advance an innovative vaccine technology to protect against current and future SARS-CoV‑2 variants and Betacoronaviruses.
